LTRN Presentation
0 likes307 views
Lantern Pharma is utilizing AI, machine learning, and genomics to innovate oncology drug discovery, significantly cutting timelines and costs compared to traditional methods. The proprietary RADR® platform aids in identifying effective drug candidates and patient populations, while facilitating the rapid launch of clinical trials. Lantern's diverse pipeline includes multiple collaborations and ongoing trials aimed at addressing unmet medical needs in cancer treatment.
LTRN Presentation
- 1. Lantern Pharma Inc. Corporate Overview NASDAQ: LTRN June 20th, 2023 Leveraging A.I., machine learning & genomics to transform the cost, pace, and timeline of oncology drug discovery and development
- 2. Forward Looking Statements 1 This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug and ADC candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug and ADC candidates and to maximize their commercial potential by advancing such candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “model,” “objective,” “aim,” “upcoming,” “should,” “will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 20, 2023. You may access our Annual Report on Form 10-K for the year ended December 31, 2022 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC’s website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this presentation represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations. NASDAQ: LTRN
- 3. “Highs and lows of drug repurposing” Current Oncology Drug Development is Costly, Risky, and Inefficient 2 A perfect problem area for artificial intelligence & machine learning 3.4% Avg. success rate of oncology drugs $2.8B R&D investment to bring a new cancer drug to market 2019 20,000+ Oncology trials conducted from 2012-2022 …are being met by data-driven, and A.I.-enabled approaches & technology Challenges in drug development… NASDAQ: LTRN 12X Success rate of oncology trials using biomarker Publications that featured Lantern’s technology
- 4. Using AI, Lantern is Transforming Drug Discovery Timelines and Cost Lantern has launched 9 programs in two years, and is anticipating launching Multiple Phase 1 trials in 2023 3 Lantern’s Drug Development Model Large Scale/Multi-omics Oncology Data Proprietary AI platform RADR® Accelerated timeline and reduced cost Transforming Early-Stage Discovery & Development Sharpening Later-Stage Clinical Trials Traditional Model Lantern’s Model 3 – 5 + Years $10 – 50 + Million 2 Years $1-5 Million “In around two years, Lantern has progressed its GBM program from initial RADR® insights, to wet lab validation, to late stage IND enabling studies - significantly cutting typical drug development timelines and cost” Reduces Significant Time & Cost Traditional Model Lantern’s Model 6 – 12 + Years $100 – 500 + Million 3-5 Years $25-100 Million “AI-driven patient stratification helps to focus clinical trials with potentially fewer and more select patients, which are more likely to respond, ultimately saving time and money” (Biopharmatrend, 2022) Reduces Significant Time & Cost (Panna Sharma) NASDAQ: LTRN
- 5. RADR® is Lantern’s AI and Machine-Learning Platform that Powers Oncology Drug Discovery and Development 4 Response Algorithm for Drug Positioning & Rescue A proprietary integrated data analytics, experimental biology, oncology-focused, machine-learning-based platform focused on drug development Discover Mechanism of Action of Any Compound or Drug 80%+ Prediction Success Patient Records 130K+ Drug-tumor interactions 154+ Advanced ML Algorithms 200+ RADR®’s Multi-Faceted AI Modules Identify and Prioritize a Compound’s Disease Indications or Subtypes Determine Optimal Drug Combinations to Improve Therapeutic Potential Generate Machine Learning-Driven Biomarker Signatures for Clinical Trial Patient Selection Characterize Specialized Attributes of a Molecule - Including Predicting Blood Brain Barrier Permeability 25+ Billion Today 50+ Billion By the end of 2023 Data points from oncology focused real-world patient and clinical data and preclinical studies NASDAQ: LTRN
- 6. RADR®‘s AI Framework Developed Actionable Insights Using Billions of Datapoints 5 Input Data RADRⓇ Derived Insights Actionable Insights Drug response Multi-omics Validation of RADRⓇ Derived Insights Identified PTGR1 as a biomarker that predicts LP-184 response Identified glioblastoma as target indication using PTGR1 PTGR1 validation using gene knockdown Validation of LP-184’s efficacy in GBM animal models FDA Orphan Drug Designation Multiple Phase 1 Trials NASDAQ: LTRN
- 7. RADR®’s Library of Over 200+ Advanced Algorithms Powers its Drug Development Capabilities 6 Ensemble Deep Learning Bayesian Based Tree Based Rule Based Clustering Others Example RADR® Algorithms Regression Classification Clustering • Diversity of algorithms allow us to handle various input data types and solve different biological problems • Lantern has filed patents for ensemble algorithms in cancer drug development • Predicting drug sensitivity values, e.g. IC50 • Predicting blood brain barrier (BBB) permeability of a compound • Predicting synergy values by combining compounds • Identifying patient populations that can be targeted through a MoA • Stratifying patients as responder, partial-responder, or non-responder • Biomarker pattern-based patient clustering • Predicting outcomes for companion diagnostic usage in a clinical trial Supervised Learning Hybrid Unsupervised Learning Examples NASDAQ: LTRN
- 8. Lantern Pharma is a Top 10 End-to-End AI Drug Discovery Company NASDAQ: LTRN 7 According to Deep Pharma Intelligence (May 04, 2022)
- 9. 8 What is the Blood-Brain-Barrier (BBB)? Blood-brain-barrier (BBB) is a highly selective border that can prevent drugs from entering brain tissues. The BBB prevents an estimated 98% of drugs from entering the brain, which presents a major hurdle for developing drugs to treat brain and central nervous system (CNS) cancers. Lantern Developed Industry Leading and Top Ranked AI Algorithms to Predict BBB Permeability of Any Compound 89-92% Highly accurate BBB permeably predictions Ultra Fast Prediction generation time in ~1 minute TOP 4 Best performing BBB prediction algorithms by The Therapeutic Commons (TDC) Scalable Capable of rapidly screening thousands of compounds simultaneously Lantern’s AI BBB permeability prediction algorithms were evaluated and scored in the BBB drug prediction challenge conducted by Therapeutics Data Commons (TDC), a coordinated initiative to evaluate AI capabilities across therapeutic modalities and stages of discovery. BBB drug prediction challenge conducted by Therapeutics Data Commons (TDC), RADR® Solves one of the Most Challenging Problems in Brain Cancer Drug Discovery – Predicting any Compound’s Blood Brain Barrier Permeability NASDAQ: LTRN
- 10. 9 ADCs are one of the Fastest Growing Drug Segments and can be Developed Faster and More Effectively with Our AI What are Antibody Drug Conjugates (ADCs)? High Specificity of Antibodies Antibody-directed killing of cancer cells, with the potential for reduced damage for normal cells High Potency of Cytotoxic Molecules Antibody Cytotoxic molecules Linker Antibody drug conjugates (ADCs) are highly specific cancer-targeted antibodies linked to potent anti-tumor small molecules and designed for the treatment of cancer $4+ billion Rapidly growing global ADC market currently valued at $14+ billion projected value by 2027 1. Significantly enhancing the selection of optimal combination ADC components including: Targeted antibodies, Antibody linkers, and Cytotoxic payloads 2. Predicting ADC antibody targeting, or immunogenicity 3. Determining ADC biomarker signatures to predict patient selection RADR® has the potential to assist advancing ADCs into first-in-human clinical trials in approximately 2 years or less by … NASDAQ: LTRN New Collaboration Established to Develop Breakthrough Antibody Drug Conjugates (ADCs) using RADR® 1. Collaboration with Bielefeld University will be led by Norbert Sewald, Ph.D. – leader of the Euro ADC consortium “MagicBullet::Reloaded” 2. RADR® ADC dev. module will be leveraged in collaboration to develop novel and potent cryptophycin-ADCs 3. Lantern receiving exclusive worldwide option to license IP from Bielefeld University related to, or generated from, collaboration
- 11. RADR® is Accelerating the Clinical Development of our Collaborators 10 Actuate Therapeutics, Inc. is a private clinical stage biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis. • Developed a breakthrough AI model to identify potential responders and non-responders from Phase 1 trial • Discovered actionable genetic biomarkers • Insights and biomarkers are informing design of an upcoming Phase 2 clinical trial • Presented advances to ML models that can accurately predict patient responses at AACR ‘23 and ASCO ‘23 annual meetings *elraglusib is a widely researched GSK-3β inhibitor. Currently, elraglusib is in multiple active Phase I/II clinical trials as a monotherapy and in combination with other agents (NCT03678883) Key RADR® AI insights for elraglusib (9-ING-41)* Future directions of collaboration • Development and application of novel RADR® algorithms and computational methods • Incorporation of new elraglusib patient data including: RNA, ctDNA, and protein biomarkers • Lantern received equity in Actuate as part of the collaboration TTC Oncology is an emerging biotechnology company founded in 2015. TTC Oncology’s mission is to develop and bring to market a novel, small-molecule therapy, TTC-352, to address the unmet needs of breast cancer patients. TTC has a license from the University of Illinois at Chicago covering the therapy. • Identify biomarker or gene signatures to power potential patient selection for an upcoming Phase 2 clinical trial • Further characterize TTC-352’s mechanism of action • Discover additional treatment indications for TTC-352 Initial aims of collaboration for TTC-352 Terms of collaboration • Lantern Pharma is receiving an exclusive right to license TTC-352, including any collaboration intellectual property (IP), during an exclusive option period About TTC Oncology’s Drug Candidate TTC-352 NASDAQ: LTRN • Phase 2 clinical trial ready drug candidate • Being developed for metastatic ER+ breast cancer • First and best in class selective human estrogen receptor partial agonist
- 12. NASDAQ: LTRN 11 owned by – Actuate Therapeutics owned by– TTC Oncology Orphan Drug Rare Pediatric Disease Collaboration partner Lantern Pharma (NASDAQ: LTRN) Starlight Therapeutics (Wholly Owned Subsidiary) RADR® Collaboration Collaboration partner Elraglusib Multiple Solid Tumors TTC-352 ER+ Breast Cancers STAR-001 Glioblastoma (GBM) Brain Mets (Lung, Breast, Skin) Atypical Teratoid Rhabdoid Tumor (ATRT) Pediatric Brain Cancers Program Indication Discovery Preclinical Phase I Phase II LP-300 Non-Small Cell Lung Cancer LP-100 Homologous Repair Deficient Cancers LP-184 Pancreatic Cancer Bladder Cancer Triple Negative Breast Cancer LP-284 Mantle Cell Lymphoma Double Hit Lymphoma ADC Select Solid Tumors Lantern’s Diverse & Unique AI Driven Pipeline of Drug Programs Lantern has 14 disclosed and collaborative drug programs including the Phase 2 Harmonic™ trial
- 13. The Harmonic™ Trial for Never Smoker Patients with NSCLC 12 Harmonic™ for LP-300 recently dosed the first patient and is actively enrolling additional trial sites and patients Patients will receive LP-300 with pemetrexed and carboplatin Patients will receive standard of care (pemetrexed and carboplatin) Trial Design: Primary Outcomes: Overall and progression free survival 1st patient Estimated Interim Results Q1 2023 Early 2024 Enrollment anticipated to last 12-18 months Market Estimate: $1.3 + Billion Annual US Cases 20,000 – 40,000 60 30 two arm, open-label, randomized trial NASDAQ: LTRN First Patient Dosed in March 2023 • Multiple additional patients + sites across the US anticipated to be enrolled during 2023 • Activated 5 sites across 12 different locations across the US • Gabrail Cancer Center • Northwest Oncology • Texas Oncology (8 locations in NY/ NJ) • New York Cancer and Blood Specialists • Cancer and Blood Specialty Clinic (OH) (IL) (CA) (TX)
- 14. Innovative and Additional Value Drivers for Never Smokers with NSCLC and their Cancer Care Community 13 NASDAQ: LTRN Harmonic™ iPhone App • First of their kind iPhone apps launched for the Harmonic™ clinical trial • The new Harmonic™ trial apps provide physicians, patients, caregivers, and the cancer community with mobile access to up-to date information 1. How NSCLC is different in never-smokers 2. What taking part in the Harmonic™ trial involves 3. How to contact the Harmonic™ clinical trial team 4. Information on the investigational new drug, LP-300 5. Locations of all currently active clinical trial sites 6. Education & awareness for the NSCLC community • Trial will collect liquid biopsies and acquire genomic/transcriptomic data from patients. Will represent one of the largest biomarker studies done on the never-smoker population. • Exploring global partnering discussions, for areas with high prevalence of never smokers with NSCLC Liquid biopsies taken at 4 time points Potential Future Clinical Trial Design & Companion Dx “ … higher in East Asia, approximately one third of all lung cancer patients are never smokers (39.7% in China, 38% in South Korea, and 32.8% in Japan)” (Zhou & Zhou, 2018) Liquid Biopsies Global Partnering Opportunities
- 15. A Nearly Doubling of Survival Outcomes Has Been Previously Observed in Never / Non Smokers with NSCLC Receiving LP-300 + Chemo.* 14 How LP-300 + Chemo Work in Never Smokers with NSCLC 2 Year Survival Overall Survival 125% median survival increase 91% median survival increase Previous Clinical Trial Results for LP-300 (NCT00966914) Never smokers have a different mutational profile compared to smokers, including more frequent but quieter mutations in the Tyrosine Kinases (TK) gene family LP-300’s Unique Mechanisms of Action • Bind and inactivate cancer causing TK’s proteins and receptors • Sensitize cancer cells to chemotherapy • Protect patients from chemotherapy side effects Combined MoAs focused on slowing growth and spread of cancer cells • LP-300 + Chemotherapy in Never Smokers with NSCLC: + 91% Overall Survival, +125% 2 Year Survival • Administered to over 1,000 people • Generally well tolerated NSCLC has a Different Molecular Profile in a Never Smoker Lung Cancer in never smokers has higher percentage of genetic mutations in Tyrosine Kinases (TK), a family of cancer- promoting genes, such as EGFR, ALK, ROS and MET *cisplatin and paclitaxel NASDAQ: LTRN
- 16. LP-300’s MoA Targets Pathways Implicated in Never Smoker with NSCLC 15 LP-300 has additional MoA’s that can give it chemo-protective and chemo-sensitization properties LP-300 Modulates Targets within Key Signaling Pathways in NSCLC • Restoring apoptosis sensitivity • Oxidative stress modulation • Anti-angiogenesis • Reduced DNA synthesis and gene expression • Reduce glutathione/thioredoxin mediated tumor resistance to therapy • Nephrotoxicity protection against chemotherapy Molecular surface of ALK with the LP-300- derived adduct at Cys1156 (yellow highlight) LP-300 adduct at Cys1235 LP-300 adduct at Cys1156 Binding site of the LP-300-derived adduct at Cys 1235 (yellow highlight) LP-300 Directly Engages with ALK Via Cysteine Modification Images of LP-300 directly binding to cysteines on ALK proteins LP-300 binding to ALK inactivates it in a dose dependent manner NASDAQ: LTRN
- 17. LP-184 has Blockbuster Potential Across Multiple Cancers as a Single Agent or in Combination Therapy 1. Unique Mechanism of Action: • Synthetic lethality • Overexpression of PTGR1 • Deficiencies in DNA Damage Repair (DDR) pathway 2. Nanomolar Potency: • Low nanomolar anti-cancer potency, healthy cells largely unaffected at these concentrations 3. Strong Growing IP Estate: • 10+ issued or pending patents & patent applications • Extensive portfolio filings in major global markets • Includes applications expiring in 2041 or later, if granted 4. FDA Orphan Drug Designation • Pancreatic cancer • Increases commercial protection and value 5. Actively Exploring Combination Therapies: • FDA Approved Agents – Spironolactone, Olaparib • Other modalities - Radiation Therapy Program Highlights 16 LP-184 Solid Tumors DDR Deficient Tumors Including: • Pancreatic Cancer • Bladder Cancer • Breast Cancer • Lung Cancer World-class collaborators Q2 2023 Summer 2023 IND application cleared by FDA Phase 1 Trial Launch Phase 1 trial in 2023* $6-7 billion Global annual market potential *Anticipated Timeline NASDAQ: LTRN
- 18. LP-184 has a Unique Mechanism of Action Leveraging Synthetic Lethality 17 LP-184’s MoA was predicted by RADR® and validated with in-vitro/in-vivo studies PTGR1 activates LP-184 into its highly potent and cytotoxic form LP-184 shows exquisite potency in cancers with deficiencies in DNA damage repair (DDR) pathways RADR® Insight (in-silico) In-vitro Gene Editing Studies (CRISPR) LP-184 in NERD Cancers LP-184 in HRD Cancers including cancers with nucleotide excision repair (NERD) and homologous repair deficiencies (HRD) In-vitro experiments confirmed the RADR® insight and that LP-184 was highly potent in cells with overexpression of PTGR1 NASDAQ: LTRN A. B. C. D.
- 19. Cancer Models with Common DNA Damage Response Deficiencies are Highly Sensitive to LP-184 Treatment NASDAQ: LTRN 18 PDX model Cancer type IC50 (nM) DDR Mutations ctg1194 NSCLC 31 ATM ctg2440 Prostate 31 PMS2 ctg1522 Pancreatic 45 ATR, BRIP1, PARP1 ctg2532 NSCLC 54 CHEK1, FANCA, NBN, RAD50 ctg3167 Prostate 54 BRCA2, ATM, FANCA, FANCI, FANCM ctg3537 Prostate 54 BRCA2, CDK12, FANCI, RAD54L, ctg0166 NSCLC 57 ATM, FANCD2, NBN ctg1643 Pancreatic 57 BRCA1, BRIP1, ctg2429 Prostate 92 ATM, ATR, PALB2, ctg0302 Pancreatic 110 BRCA2, ATM, BLM, FANCA ctg1680 NSCLC 140 PARP2 ctg0192 NSCLC 200 BRCA1, RAD54L ctg3337 Prostate 230 RAD51C ctg0314 Pancreatic 270 BRCA2, CDK12, PALB2 ctg0381 Pancreatic 2,900 ATM, BRCA1, BRCA2 • Across 10 TNBC PDX mouse models LP-184 treatment resulted in 107- 141% tumor growth inhibition • All 10 TNBC PDX models were HR deficient • 7/10 TNBC models were resistant to PARP inhibitors Olaparib/ Niraparib and to doxorubicin/ cyclophosphamide LP-184 Completely Inhibits Tumor Growth in Triple Negative Breast Cancer (TNBC) PDX Mouse Models • PDX-derived cell lines with mutations in key HR and NER genes are highly sensitive to LP-184 • Only 1 model was not highly sensitive to LP-184 (highlighted in blue) % Tumor Volume Change
- 20. LP-184 Treatment Results in Complete Regression in DNA Damage Repair (DDR) Deficient Pancreatic Cancer PDX Models 19 LP-184 Vehicle CTG-1522 Tumors CTG-1643 Tumors When treated with LP-184, CTG-1522 and CTG-1643 models showed a tumor growth inhibition of >100% 0 10 20 30 40 50 0 300 600 900 1200 1500 1800 2100 Days After Treatment Tumor Volume mm 3 Vehicle (CTG-1522) LP-184 (CTG-1522) Vehicle (CTG-1643) LP-184 (CTG-1643) *CTG-1522 – ATR Frameshift mutation, non responder to FOLFIRINOX CTG-1643 - BRCA1 Frameshift mutation In-vitro PDX pancreatic mouse models treated with LP-184 0 10 20 30 40 50 0 300 600 900 1200 Days After Treatment Tumor Volu Vehicle (CTG-1522) LP-184 (CTG-1522) Vehicle (CTG-1643) LP-184 (CTG-1643) 0 10 20 30 40 50 0 300 600 900 1200 1500 Days After Treatment Tumor Volume Vehicle (CTG-1522) LP-184 (CTG-1522) Vehicle (CTG-1643) LP-184 (CTG-1643) 0 10 20 30 40 50 0 300 600 900 1200 1500 1800 Days After Treatment Tumor Volume mm Vehicle (CTG-1522) LP-184 (CTG-1522) Vehicle (CTG-1643) LP-184 (CTG-1643) 0 10 20 30 40 50 0 300 600 900 1200 1500 1800 2100 Days After Treatment Tumor Volume mm 3 Vehicle (CTG-1522) LP-184 (CTG-1522) Vehicle (CTG-1643) LP-184 (CTG-1643) Key Highlights of LP-184 for Pancreatic Cancer • LP-184 exhibits nanomolar potency in PTGR1 overexpressing tumors with DDR deficiencies • Positioned for 2nd and 3rd line treatment, where there is unmet need for novel therapies • Combination therapy potential with SOC agents: Spironolactone, PARP inhibitors, Gemcitabine, Irinotecan, Oxaliplatin • Phase 1 clinical trial anticipated for Q2 2023 • FDA Orphan Drug Designation granted for LP-184 to treat pancreatic cancer NASDAQ: LTRN A. B.
- 21. Combining LP-184 with SOC Agents Significantly Enhances its Potency 20 In-vivo LP-184 has synergy with several SOC agents including Spironolactone, Radiation Therapy, and others. 8 12 16 20 24 28 32 36 40 44 0 500 1000 1500 2000 Tumor Volume (mm 3 ) Vehicle Spironolactone LP-184 LP-184 + Spironolactone LP-184 Dosing Days Post Implantation LP-184 + Spironolactone in GBM in vivo mouse model LP-184 + Radiation in the Panc03.27 CDX Model • Spironolactone is an FDA approved agent that can impair DNA damage repair pathways • Combination of LP-184 or LP-284 with Spironolactone: 1) Enhances potency 2) Decreases expected dose needed for treatment 3) Exploits MoA of both drugs • Terminal tumor volumes from the RT + LP-184 treatment group are significantly (**p < 0.01) smaller than treated with RT or LP-184 alone • Mean tumor volumes of RT + LP184 were ~1.8 fold lower than tumors treated with LP-184 alone NASDAQ: LTRN A. B.
- 22. LP-184's Phase 1A Trial is Anticipated to Launch and Start Enrollment in Summer 2023 21 • Anticipated Phase 1A Clinical Trial Dates • IND application cleared by FDA – June 2023 • Trial launch & 1st patient dosed – Summer 2023 • Clinical Trial Design • Bayesian optimal interval (BOIN) design • Anticipated starting dose of 0.015 mg/kg, based off IND enabling studies in dogs • Targeting up to 30-35 patients • Future clinical trial sites anticipated at top comprehensive centers in the US: • Fox Chase Cancer Center • Johns Hopkins • Multiple additional sites Dose Level 1 (n ≥ 3, BOIN*) Dose Level 2 (n ≥ 3, BOIN) Dose Level 3 (n ≥ 3, BOIN) Dose Level 4 (n ≥ 3, BOIN) Dose Level 5 (n ≥ 3, BOIN) Dose Level 8 (n ≥ 3, BOIN) MTD* / MAD* Dose Level 8 (n=10 total) Dose Level 7 (n=10 total) (As Needed) *MTD- Maximum tolerated dose *MAD- Maximum administered dose *BOIN- Bayesian Optimal Interval LP-184 Clinical Trial Updates and Design Recommended Dose Range of LP-184 NASDAQ: LTRN LP-184 Phase 1A Trial Design
- 23. LP-284 was Developed from RADR® Insights to Late-Stage IND Enabling Studies in Less Than 2 Years for Non-Hodgkin’s Lymphomas 22 Program Highlights • LP-284 has nanomolar potency against several aggressive non-Hodgkin’s lymphomas (NHL) including mantle cell and double hit • In-vivo LP-284 can rescue tumors resistant to MCL standard-of-care agents Ibrutinib and Bortezomib • Enhanced potency when used in combination with other approved agents like Spironolactone • FDA granted Orphan Drug Designation for mantle cell lymphoma • Results from preclinical studies have been published at ASH ’21 & ’22, SOHO ‘22, and Oncotarget • Received notice of allowance from the USPTO for the composition of matter patent, no. 17/192,838, covering the molecule LP-284 *Anticipated Timeline Phase 1 Trial Launch in 2023* LP-284 for non-Hodgkin’s B-cell lymphomas • Mantle Cell Lymphoma • Double Hit Lymphoma Q2 2023 Q3 2023 2023 Complete IND enabling studies and file IND application with the FDA Phase 1 Trial Launch LP-284 $1.2 billion U.S. & Europe annual market potential NASDAQ: LTRN
- 24. LP-284 Treatment Demonstrates Stronger Anti-Tumor Potential in Mouse Models Compared to Current MCL Therapies 23 A. B. LP-284 Significantly Decreases MCL Tumor Volumes in Mice vs Standard of Care Agents LP-284 Increases Probability of Survival in Mice vs Standard of Care Agents NASDAQ: LTRN
- 25. Superior Responses to LP-284 are Observed in Several Non-Hodgkin’s B-Cell Lymphomas Including Those Resistant to SOC Agents 24 NHL cell lines are sensitive to LP-284 treatment LP-284 can rescue tumors resistant to SOC agents LP-284 exhibits nanomolar potency in numerous non- Hodgkin’s lymphomas cell lines including: mantle cell, double- hit, Burkitt’s, double expressor, and anaplastic large cell lymphoma In cell derived xenograft MCL models, LP-284 can completely rescue tumors that are resistant to the SOC agents Bortezomib and Ibrutinib NASDAQ: LTRN A. B.
- 26. Starlight Therapeutics’ CNS and Brain Cancer Programs were Born from Billions of Datapoints and AI • $5-6 Billion Annual Market Potential* • Multiple Clinical-stage CNS Cancer Indications • 500,000+ Potential CNS Patients Globally* • 4 US Patents & Patent Applications and 10+ Foreign Pending Patent Applications *Estimated Annual Global Numbers • STAR-001 has been Granted FDA Orphan Drug and Rare Pediatric Disease Designations • World Class Collaborators from Johns Hopkins and UT Health San Antonio There are over 120 types of central nervous system (CNS) and brain cancers and a majority have no effective treatment options 5 Year Survival Rates of CNS And Brain Cancers Remain Low Despite Advances in Cancer Therapies • No effective single-agent therapies have been approved for glioblastoma (GBM) in over 17 years • Effective therapies are needed to improve outcomes for brain mets. patients • There are no approved therapies for atypical teratoid rhabdoid tumors (ATRT) • CNS indications were developed using AI in less than 2 years 10% BRAIN METS. (TNBC*) 7% GBM 32% ATRT *Triple Negative Breast Cancer 25
- 27. Multiple Clinical Trials are Planned for STAR-001 Glioblastoma $1.5-2 billion Annual US Cases 13K ATRT & Pediatric CNS $0.1 billion ATRT Annual US Cases 600+ Brain Mets. (Lung, Breast) $3 billion Annual US Cases 100K Other HGGs $1.2 billion Annual US Cases 22K STAR-001 has Multi-billion Market Potential In CNS Cancers $5-6 billion (USD) Global Annual Estimated Market Potential • Upcoming Phase 1 trial for pediatric CNS cancers • Nanomolar potency gives multiple shots on goal in CNS cancers • Upcoming Phase 2 trials for adult CNS cancers • Excellent blood brain barrier permeability • Improved bioavailability over current SOC Agents • Target CNS indications have limited or no effective therapies 26 ADULT CNS CANCERS PEDIATRIC CNS CANCERS Atypical Teratoid Rhabdoid Tumors (ATRT) Diffuse Intrinsic Pontine Glioma (DIPG) - Orphan Drug Designation - Rare Pediatric Disease Designation Glioblastoma (GBM) Other High-Grade Gliomas (HGG) Brain Mets. (Triple Negative Breast Cancer) Brain Mets. (Non-Small Cell Lung Cancer) Brain Mets. (Melanoma) PediatricCNS indicationswill enterclinicaltrial aftertheAdult Phase1trialsbegin Phase 3 Phase 2 Phase 1A Preclinical Discovery IND Enabling Phase 1A will be conducted by Lantern Pharma
- 28. Intellectual Property Portfolio Builds Expanding Protections with Additional Barriers to Competition 27 90+ Issued Patents & Pending Applications 5 families Drug Sensitivity & Response Signatures using Biomarkers 7 families Methods of Use 2 families Composition of Matter LP-300 • Acquired • Recent patent (no. 11,471,431) • Commercial protection extended to late 2032 FDA Orphan Drug Designation • Granted for Pancreatic Cancer, GBM, and Malignant Gliomas in Aug. 2021, for ATRT in Jan. 2022, and for Mantle Cell Lymphoma in Jan. 2023 • Provides 7 years of market exclusivity • Complements patent protections • Reduces costs or provides waivers for marketing/registration fees • Reduces annual product fees • Assistance for expedited program development Pediatric Rare Disease Designation • Granted in Jan. 2022 for ATRT • Eligibility for potential priority review voucher if applicable and approved • Priority review voucher can sell in marketplace for $100-$120 million LP-184 • In-licensed • Internally developed LP-284 • Internally developed • Composition of matter patent (no. 17/192,838) • Commercial protection into 2039 RADR® Additional Commercial Protections NASDAQ: LTRN
- 29. z Recent Publications and Posters Highlighting the Strong Validation of RADR® Insights, De-risking the Development of Lantern’s Drug Candidates 28 Artificial intelligence platform, RADR®, aids in the discovery of DNA damaging agent for the ultra- rare cancer Atypical Teratoid Rhabdoid Tumors Recent Posters/ Publications American Society of Hematology LP-184, an acylfulvene class small molecule therapeutic, is synthetically lethal in HR deficient and PARP inhibitor resistant triple negative breast cancer Preclinical efficacy of LP-184, a tumor site activated synthetically lethal therapeutic, in glioblastoma Development of a Potent DNA Damaging Agent LP-284 for Treatment of Mantle Cell Lymphoma NASDAQ: LTRN Oct 2022 Nov 2022 Dec 2022 Dec 2022 LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair June 2023 LP-184, an acylfulvene class small molecule therapeutic, is synthetically lethal in DNA damage repair deficient cancers Apr 2023
- 30. 29 ● Advance enrollment of The Harmonic™ Trial & increase patient/clinician awareness ● Launch clinical trials for LP-184 and LP-284 ● Progress LP-184 (STAR-001) towards Ph. 1 / 2 pediatric clinical trial, including ATRT ● Advance ADC preclinical development to support future Phase 1 launch and/or partnership ● Explore combinations for LP-100, LP-184, LP-284, and LP-300 with other existing approved drugs ● Expand RADR® AI platform to 50 billion datapoints ● Establish additional RADR® based collaborations with companies and research partners ● Explore licensing and partnership opportunities with biopharma companies ● Continue disciplined fiscal management A Transformational year for Lantern 2023Objectives NASDAQ: LTRN
- 31. Financial Highlights And Cap Table 30 Solid financial position and capital efficiency fuel continued growth and give Lantern cash runway into 2025 *Market Cap based on shares outstanding at 3/31/23. L A N T E R N P H A R MA IN C . (LT R N ) Exchange Nasdaq Stock Price (6/16/23) $6.01 Common Shares Outstanding (3/31/23) 10.86M Market Cap (6/16/23)* $65.25M Warrants (3/31/23) 178K Options (Employees, Management and Directors) (3/31/23) 1.1M Fully Diluted Shares Outstanding (3/31/23) 12.13M • Approx. $51.5M of cash, cash equivalents and marketable securities as of March 31, 2023 • Committed to creating enduring growth and value for LTRN shareholders NASDAQ: LTRN
- 32. Franklyn Prendergast, M.D., Ph.D. Panna Sharma Maria Maccecchini, Ph.D. Lantern’s Board of Directors 31 Donald “Jeff” Keyser, J.D., MPH, Ph.D. Vijay Chandru, Ph.D. David Silberstein, Ph.D. Non-executive Chairman CEO and President NASDAQ: LTRN
- 33. Investment Highlights 32 Lantern Pharma (NASDAQ: LTRN) Focused on cancer drug market segments with clear clinical need, understood mechanisms, targeted patient populations that exceed 1 million , and multi-billion USD in annual sales potential Proven and growing library of AI & machine-learning methodologies published at ASCO, AACR, and SNO used to generate novel IP & patents and accelerate discovery by potentially years Growing AI based platform with clear roadmap to 50+ Bn. datapoints focused exquisitely on cancer therapeutic development and companion Dx in a high growth, high demand $12+ Bn. market Active drug rescue process and in the clinic with 2 compounds and accelerating additional compounds and combinations to clinical trials…potentially saving tens of millions of dollars and years of development Experienced and innovative management team w/ 70+ years experience in cancer and a passion to change the cost and outcome for cancer patients by using AI and genomics – paradigm changing technologies A novel ADC platform with the potential to develop and out-license or partner ADC assets in early phases Several compounds in place with multiple targeted indications, including LP-184 (received Orphan Disease Designations in pancreatic and GBM & Rare Pediatric Disease Designation for ATRT), which can help accelerate development Industry leading collaborations with National Cancer Institute, Georgetown, Johns Hopkins, UT Health San Antonio & Fox Chase Cancer Center NASDAQ: LTRN
- 34. Nasdaq: LTRN IR Contact: [email protected] 1-972-277-1136 CONNECT WITH US 33 www.lanternpharma.com @LanternPharma Sign up for Newsletter www.lanternpharma.com/media/newsletter#subscriptionSec